IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 25,250
-1,150 (-4.36%)
At close: Jun 5, 2026
IntoCell Revenue
IntoCell had revenue of 281.15M KRW in the quarter ending March 31, 2026, with 157.55% growth. This brings the company's revenue in the last twelve months to 2.47B, down -15.82% year-over-year. In the year 2025, IntoCell had annual revenue of 2.30B, down -20.86%.
Revenue (ttm)
2.47B
Revenue Growth
-15.82%
P/S Ratio
153.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
379.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.30B | -605.91M | -20.86% |
| Dec 31, 2024 | 2.91B | 1.29B | 79.72% |
| Dec 31, 2023 | 1.62B | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 140.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 110.50B |
| NIBEC | 32.34B |
| Genome & Company | 24.02B |
| S.Biomedics | 16.48B |
| Kangstem Biotech | 3.42B |
| Inventage Lab | 3.16B |
| Y-Biologics | 2.79B |
| curacle co.,ltd. | 1.06B |